NO985607L - FremgangsmÕte for fremstilling av indol-derivater - Google Patents

FremgangsmÕte for fremstilling av indol-derivater

Info

Publication number
NO985607L
NO985607L NO985607A NO985607A NO985607L NO 985607 L NO985607 L NO 985607L NO 985607 A NO985607 A NO 985607A NO 985607 A NO985607 A NO 985607A NO 985607 L NO985607 L NO 985607L
Authority
NO
Norway
Prior art keywords
alkyl
hydrogen
compound
aryl
formula
Prior art date
Application number
NO985607A
Other languages
English (en)
Other versions
NO985607D0 (no
Inventor
John Eugene Macor
Martin James Wythes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24393510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO985607(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of NO985607L publication Critical patent/NO985607L/no
Publication of NO985607D0 publication Critical patent/NO985607D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Lasers (AREA)
  • Electroluminescent Light Sources (AREA)

Abstract

Fremgangsmåte for fremstilling av et indolderivat som er egnet som mellomprodukt for fremstilling av terapeutisk aktive forbindelser. Forbindelsen som fremstilles har formelen (V) hvor W er -COjRn eller R3; Q er CH2 eller C=O; n er O, l eller 2; Rj er hydrogen; R2 er valgt fra halogen, cyano, OR,, - (CH2).-(C=O)NR5R6, - (CH2) ,-SO2NR5R6, -(CH2)0-NR7(C=0)Re, -(CH2)n-S(0)xRe og -CH=CH (CH2) yR^; x er l eller 2; m er O, l, 2 eller 3; R3 er valgt fra hydrogen og Cx.s lineær eller forgrenet alkyl; R, er valgt fra hydrogen og C^j alkyl; R5 og R6-er uavhengig valgt fra hydrogen og C^, alkyl, eller R5 og R6 sammen danner en 4-, 5- eller 6-leddet mettet, karbocyklisk ring; R, og Re er uavhengig valgt fra hydrogen, C^, alkyl, aryl og Ci.j alkyl-aryl; R10 er valgt fra -(C=0)NR5RS, -SO2NRSR6, -NR,(C=O)R8, -NR,SO2R,, -S(O)XR8 o"g -NR,(C=O)ORB, hvor R5, R6, R7, Re og x er som angitt ovenfor; y er O, l eller 2; Rtl er valgt fra Cj^alkyl, benzyl og aryl; og de ovenfor angitt arylgrupper og aryl-delene i de ovenfor angitte alkylaryl-grupper er uavhengig valgt fra fenyl og substituert fenyl, hvor den substituerte fenylgruppen kan være substituert med en til tre grupper valgt fra d_4 alkyl, halo- gen, hydroksy, cyano, karboksamido, nitro og C^, alkoksy, særlig i R-enantiomer form. Forbindelsen fremstilles ved (a) når W er -CO2RU og Rt, R2, Ru og Q er som angitt ovenfor, omsetning av en forbindelse med formelen (IV) hvor R! og R2 er som angitt ovenfor, med et syreklorid av N- COjRn-prolin, N-C02Rn-azetidin-2-karboksylsyre eller N-C02Rn- pipekolinsyre; eller (b) når W er R3, Q er CH2 og R2 er -CH=CH (CH2) yR^ og Rlf R3 og R10 er som angitt ovenfor, omsetning av en forbindelse med formel V hvor R2 er halogen, W er R3, Q er CH2 og Rj og R3 er som angitt ovenfor, med en forbindelse med formelen CHj^CHfCHjJyRu, hvor R10 er som angitt ovenfor, under anvendelse av overgangsmetall-katalyse.
NO985607A 1990-10-15 1998-12-01 FremgangsmÕte for fremstilling av indol-derivater NO985607D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59792890A 1990-10-15 1990-10-15
PCT/US1991/007194 WO1992006973A1 (en) 1990-10-15 1991-10-08 Indole derivatives

Publications (2)

Publication Number Publication Date
NO985607L true NO985607L (no) 1998-12-01
NO985607D0 NO985607D0 (no) 1998-12-01

Family

ID=24393510

Family Applications (3)

Application Number Title Priority Date Filing Date
NO931378A NO305121B1 (no) 1990-10-15 1993-04-14 AnalogifremgangsmÕte for fremstilling av terapeutisk aktive indol-derivater
NO985607A NO985607D0 (no) 1990-10-15 1998-12-01 FremgangsmÕte for fremstilling av indol-derivater
NO2001019C NO2001019I1 (no) 1990-10-15 2001-11-09 Eletriptan

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO931378A NO305121B1 (no) 1990-10-15 1993-04-14 AnalogifremgangsmÕte for fremstilling av terapeutisk aktive indol-derivater

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2001019C NO2001019I1 (no) 1990-10-15 2001-11-09 Eletriptan

Country Status (33)

Country Link
EP (1) EP0592438B1 (no)
JP (2) JP2575272B2 (no)
KR (1) KR0179053B1 (no)
CN (1) CN1039322C (no)
AT (1) ATE157361T1 (no)
AU (1) AU651637B2 (no)
BG (1) BG61975B1 (no)
BR (2) BR9106978A (no)
CA (1) CA2091562C (no)
DE (3) DE69127468T2 (no)
DK (1) DK0592438T5 (no)
EG (1) EG20224A (no)
ES (1) ES2104733T3 (no)
FI (1) FI105812B (no)
GR (1) GR3025087T3 (no)
HU (2) HUT64326A (no)
IE (1) IE913555A1 (no)
IL (3) IL115117A (no)
LU (1) LU90902I2 (no)
MX (1) MX9101606A (no)
MY (1) MY111683A (no)
NL (1) NL300070I2 (no)
NO (3) NO305121B1 (no)
NZ (2) NZ270675A (no)
OA (1) OA09874A (no)
PL (3) PL168919B1 (no)
PT (1) PT99218B (no)
RO (1) RO111767B1 (no)
RU (1) RU2095360C1 (no)
SG (1) SG54270A1 (no)
WO (1) WO1992006973A1 (no)
YU (1) YU48088B (no)
ZA (1) ZA918156B (no)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
RU2126399C1 (ru) * 1991-11-25 1999-02-20 Пфайзер Инк. Производные индола, замещенные индолы и способ ингибирования 5ht1 рецептора серотонина
TW288010B (no) * 1992-03-05 1996-10-11 Pfizer
PL172405B1 (en) * 1992-04-07 1997-09-30 Pfizer Derivatives of indole
WO1993021180A1 (en) * 1992-04-10 1993-10-28 Pfizer Inc. Acylaminoindole derivatives as 5-ht1 agonists
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
GB9208161D0 (en) * 1992-04-14 1992-05-27 Pfizer Ltd Indoles
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
TW251284B (no) * 1992-11-02 1995-07-11 Pfizer
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
IT1271352B (it) * 1993-04-08 1997-05-27 Boehringer Ingelheim Italia Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
CZ274595A3 (en) * 1993-04-22 1996-03-13 Pfizer Res & Dev Indole derivatives, processes of their preparation and use as well as pharmaceutical compositions based thereon
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.
ES2070772B1 (es) * 1993-08-09 1996-02-16 Pfizer Derivados de acilaminoindol
AU686654B2 (en) * 1993-08-31 1998-02-12 Pfizer Inc. 5-arylindole derivatives
US5965582A (en) * 1994-08-03 1999-10-12 Asta Medica Aktiengesellschaft N-benzylindole and benzopyrazole derivatives with anti-asthmatic, anti-allergic, anti-inflammatory and immunemodulating effect
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
AU726560B2 (en) * 1994-10-12 2000-11-09 Pfizer Research And Development Company, N.V./S.A. Use of indole derivatives for the treatment of various diseases
ES2181791T3 (es) * 1994-10-12 2003-03-01 Pfizer Res & Dev Derivados de indol para el tratamiento de la migraña.
GB9420529D0 (en) * 1994-10-12 1994-11-30 Pfizer Ltd Indoles
GB9424471D0 (en) * 1994-12-03 1995-01-18 Pfizer Ltd Treatment of emesis
PL322843A1 (en) * 1995-03-20 1998-02-16 Lilly Co Eli 5-substituted 3-91,2,3,6-tetrahydropyridin-4-yl)- and 3-9piperydin-4-4-yl0-1h-indoles nevel 5-htif natagonists
GB9510223D0 (en) * 1995-05-20 1995-07-19 Pfizer Ltd Therapeutic agent
US5945118A (en) * 1995-09-29 1999-08-31 Pfizer Inc Indole derivative for the treatment of migraine
GB9714383D0 (en) * 1997-07-08 1997-09-10 Pfizer Ltd Improved process
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
WO1999053956A1 (en) * 1998-04-16 1999-10-28 Yamanouchi Pharmaceutical Co., Ltd. Remedies for obesity
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
DE19858340A1 (de) * 1998-12-17 2000-06-21 Merck Patent Gmbh Verfahren zur Herstellung von 3-Alkanoyl- und 3-Alkylindolen
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
JP2000336074A (ja) 1999-03-24 2000-12-05 Sumitomo Chem Co Ltd ［２−（アリールスルホニル）エテニル］ベンゼン誘導体の製造方法
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
EP1207153A1 (en) * 1999-08-26 2002-05-22 Fujisawa Pharmaceutical Co., Ltd. Process for the preparation of indole derivatives or salts thereof
GB9923314D0 (en) 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
FR2799463B1 (fr) * 1999-10-12 2004-04-16 Adir Nouveaux composes cyano-indoles inhibiteurs de recapture de serotonine, leur procede de preparation et ces compositions pharmaceutiques qui les contiennent
CN1814596A (zh) * 2000-04-28 2006-08-09 阿卡蒂亚药品公司 毒蕈碱性激动剂
US20030166704A1 (en) 2000-12-20 2003-09-04 Pfizer Inc. New process
GB0031094D0 (en) * 2000-12-20 2001-01-31 Pfizer Ltd New Process
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
EP1419151B1 (en) 2001-08-15 2014-02-26 Pharmacia & Upjohn Company LLC Chrystals including a malic acid salt of n-[2-(diethylamino)ethyl] -5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene)methyl] -2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
CA2529528A1 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
USD571213S1 (en) 2005-05-12 2008-06-17 Pepsico, Inc. Portion of a bottle
US7645786B2 (en) 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
KR20080016648A (ko) 2005-06-15 2008-02-21 화이자 리미티드 기생충 방제용 치환된 아릴피라졸
WO2006079999A2 (en) * 2006-04-09 2006-08-03 Barth Frederik H Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist
US20090299077A1 (en) * 2008-05-22 2009-12-03 Vinod Kumar Kansal Salts of (R)-5-(2phenylsulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole, 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole and of eletriptan
CA2729346A1 (en) 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
EP2149573A1 (en) * 2008-08-01 2010-02-03 Laboratorios Del. Dr. Esteve, S.A. Substituted indole sulfonamide compounds their preparation and use as medicaments
IT1393700B1 (it) * 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint Sintesi di 3-{[(2r)-1-metilpirrolidin-2-il]metil}-5-[2-(fenilsulfonil)etil]-1h-indolo
WO2011004391A2 (en) 2009-06-25 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of eletriptan and its salt thereof
WO2011024039A1 (en) * 2009-08-25 2011-03-03 Ramesh Babu Potluri Synthesis of novel 5-(2-(phenylsulfonyl)ethyl)-1h-indole derivatives
WO2011089614A1 (en) * 2010-01-19 2011-07-28 Sms Pharmaceuticals Limited PROCESS FOR PREPARING ELETRIPTAN HYDROBROMIDE HAVING α-FORM
CN102606426B (zh) * 2012-03-02 2014-05-21 王仲彦 踏步健身发电装置
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103408535B (zh) * 2013-08-13 2016-03-02 张家港威胜生物医药有限公司 一种依来曲普坦中间体-5-溴-3-(n-甲基吡咯啉-2-基甲基)-1h-吲哚合成工艺
CN107530318A (zh) 2015-03-02 2018-01-02 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
JP2019502761A (ja) 2016-01-21 2019-01-31 ラボラトリオス レヴィ エセエレ （（ｒ）−３−［（−１−メチルピロリジン−２−イル）メチル］−５−（２−フェニルスルホニルエチル）−１ｈ−インドールを作製する方法
CN106065008B (zh) * 2016-06-16 2018-06-05 黑龙江中医药大学 一种具有改善睡眠作用的吲哚-2-酰胺类化合物及其应用
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
TR201616365A1 (tr) 2016-11-14 2018-05-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deksketoprofen ve eletri̇ptanin oral farmasöti̇k kompozi̇syonlari
TR201619983A2 (tr) 2016-12-29 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇klofenak ve eletri̇ptanin farmasöti̇k formülasyonlari
KR102129947B1 (ko) 2018-06-08 2020-07-03 김종창 콘크리트 타설을 위한 입체형 와이어 메쉬
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan
US20230346746A1 (en) 2020-01-22 2023-11-02 Technophage, Investigaçäo E Desenvolvimento Em Biotecnologia, S.A. Eletriptan hydrobromide for treatment of spinal cord injury and improvement of locomotor function
US20250171456A1 (en) * 2022-02-01 2025-05-29 Caamtech, Inc. Psychedelic compounds and their therapeutic uses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL74527C (no) *
US2773875A (en) * 1952-03-28 1956-12-11 Hoffmann La Roche Indole derivatives and method for producing same
GB886684A (en) * 1957-09-17 1962-01-10 Upjohn Co Improvements in or relating to heterocyclic compounds and the manufacture thereof
GB851780A (en) * 1958-02-25 1960-10-19 Rhone Poulenc Sa New indole derivatives
US3037031A (en) * 1959-08-04 1962-05-29 Warner Lambert Pharmaceutical Derivatives of 3-(2-aminoalkyl)-5-indolol and process therefor
GB893707A (en) * 1960-03-01 1962-04-11 Roche Products Ltd Novel tryptamine derivatives and a process for the manufacture thereof
GB966562A (en) * 1961-04-06 1964-08-12 Parke Davis & Co Amine compounds and means of producing the same
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
BG61975B1 (bg) 1998-11-30
PT99218A (pt) 1992-09-30
IE913555A1 (en) 1992-04-22
KR0179053B1 (ko) 1999-03-20
ATE157361T1 (de) 1997-09-15
RO111767B1 (ro) 1997-01-30
MY111683A (en) 2000-11-30
DE9190141U1 (de) 1993-07-15
NL300070I1 (nl) 2002-02-01
HU225055B1 (en) 2006-05-29
IL99701A (en) 1996-10-31
HU9301098D0 (en) 1993-07-28
IL115117A0 (en) 1995-12-08
CA2091562A1 (en) 1992-04-16
AU651637B2 (en) 1994-07-28
LU90902I2 (fr) 2002-06-26
DE69127468D1 (de) 1997-10-02
EP0592438A1 (en) 1994-04-20
YU48088B (sh) 1997-01-08
DE10299004I2 (de) 2006-03-16
PT99218B (pt) 1999-04-30
JPH093063A (ja) 1997-01-07
DK0592438T3 (da) 1997-09-29
DK0592438T5 (da) 1999-12-06
DE10299004I1 (de) 2002-05-08
EP0592438B1 (en) 1997-08-27
NO305121B1 (no) 1999-04-06
NO2001019I1 (no) 2001-12-03
RU2095360C1 (ru) 1997-11-10
MX9101606A (es) 1992-06-05
NL300070I2 (nl) 2002-03-01
IL99701A0 (en) 1992-08-18
CN1039322C (zh) 1998-07-29
NZ240217A (en) 1995-05-26
NO931378D0 (no) 1993-04-14
CA2091562C (en) 2001-03-27
WO1992006973A1 (en) 1992-04-30
EG20224A (en) 1997-12-31
NO985607D0 (no) 1998-12-01
ZA918156B (en) 1993-04-14
FI931667A0 (fi) 1993-04-14
GR3025087T3 (en) 1998-01-30
HUT64326A (en) 1993-12-28
OA09874A (en) 1994-09-15
FI105812B (fi) 2000-10-13
NO931378L (no) 1993-04-14
FI931667A7 (fi) 1993-04-14
SG54270A1 (en) 1998-11-16
JPH05507288A (ja) 1993-10-21
JP2575272B2 (ja) 1997-01-22
BR9106978A (pt) 1993-09-28
AU8950491A (en) 1992-05-20
YU165391A (sh) 1994-01-20
NZ270675A (en) 1997-07-27
PL168919B1 (pl) 1996-05-31
ES2104733T3 (es) 1997-10-16
BG97632A (bg) 1994-03-31
PL170330B1 (pl) 1996-11-29
PL169987B1 (en) 1996-09-30
IL115117A (en) 1996-11-14
JP2677777B2 (ja) 1997-11-17
DE69127468T2 (de) 1998-01-02
BR1100080A (pt) 2000-06-06
CN1062529A (zh) 1992-07-08

Similar Documents

Publication Publication Date Title
NO985607L (no) FremgangsmÕte for fremstilling av indol-derivater
SE7607566L (sv) Forfarande for framstellning av 1,4-dihydropyridinderivat
PT97888A (pt) Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem
DK446279A (da) Fremgangsmaade til fremstilling af substituerede 1-carba-2-penem-3-carboxylsyrer
DK136191A (da) 1h-imidazo/4,5-c/quinolinderivat
ES431055A1 (es) Procedimiento para la preparacion de nuevos n- (metoximetil-furilmetil)-6, 7-benzomorfanos y -morfinanos.
DK0984942T3 (da) Flydende benz-iso-quinolinderivater
ES382550A1 (es) Procedimiento para la preparacion de nuevas 2-aminoalcohi- lamino-tieno (3,2-d) pirimidinas.
TR199700184A2 (xx) Aminoalkil ve asilaminoalkil eterleri, bunlar�n �retilmesine mahsus usul ve bradikinin resept�r antagonistleri olarak kullan�lmalar�.
ES8704480A1 (es) Un procedimiento para la preparacion de derivados de 1,4-dihidropiridina.
GB1049315A (en) Dyestuffs
NO923153L (no) Indol-derivater, deres fremstilling og bruk
SE7510787L (sv) Nya kvevehaltiga, polycykliska foreningar, salter derav och deras optiska antipoder, jemte sett for deras framstellning
ES383006A1 (es) Un procedimiento para la preparacion de compuestos utiles como agentes neurolepticos.
FR2448540A1 (fr) Procede de preparation de composes de tryptamine
SE8605531L (sv) Azoniaspironortropanolester
ES306767A1 (es) Procedimiento para la preparacion de nuevos derivados basicos de tiepina y oxepina.
CH608785A5 (en) Process for producing new N-acylglutamines
SE7910387L (sv) 7alfa-metoxicefalosporinderivat och forfarande for framstellning derav
NZ331180A (en) Specific immunophilin ligands with indole structure as antiasthmatics and immunosuppressants
ES417884A1 (es) Procedimiento para la preparacion de derivados de bifenilo.
DK0756593T3 (da) Fremgangsmåde til fremstilling af 2-piperazincarboxylsyrederivater
ES466305A1 (es) Un procedimiento para la preparacion de una sal con un ami- noazucar basico o un aminoacido basico, de un derivado de benzopirano.
ES477646A1 (es) Un procedimiento para preparar derivados de tiazol.
JPS51133271A (en) Process for preparing heterocyclic compounds